Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and hepatic disorders.. ..Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change in HbA1c from baseline in those with hepatic disorders was − … Continue reading Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Rate This

Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics and unaware of having NAFLD. At the visit, volunteers were … Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Rate This

#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS The subgroup of 2,605 patients with heart failure and reduced … Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Rate This

PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans

Pregnancy is a physiological state of continuous adaptation to changing maternal and fetal nutritional needs, including a reduction of maternal insulin sensitivity allowing for appropriately enhanced glucose availability to the fetus. However, excessive insulin resistance in conjunction with insufficient insulin secretion results in gestational diabetes mellitus (GDM), greatly increasing the risk for pregnancy complications and predisposing both mothers and offspring to future metabolic disease. Here, … Continue reading PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans

Rate This

Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes

Aims To evaluate the effect of oral semaglutide on energy intake and appetite in subjects with type 2 diabetes (T2D). Materials and methods In this randomised, double‐blind, placebo‐controlled, two‐period cross‐over trial, 15 subjects with T2D received 12 weeks’ treatment with once‐daily oral semaglutide (4‐week dose‐escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa. Energy intake was measured during an ad … Continue reading Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes

Rate This

Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

The ability to differentiate patient populations with type 2 diabetes at high risk of severe hypoglycaemia could impact clinical decision making. The aim of this study was to develop a risk score, using patient characteristics, that could differentiate between populations with higher and lower 2‐year risk of severe hypoglycaemia among individuals at increased risk of cardiovascular disease. Two models were developed for the risk score … Continue reading Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

Rate This

Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

To examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships. A retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes), with linkage to hospital and mortality data. We identified 101 749 … Continue reading Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

Rate This

#Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult

This study investigates the association of smoking cessation and postcessation weight gain with the development of type 2 diabetes mellitus and hypertension. Methods A total of 96,524 individuals without diabetes mellitus and hypertension aged ≥20 years between 2006 and 2008 were included, with follow-up until December 31, 2015. Smoking status and weight changes were monitored for 2 years. Hazard ratios and 95% CIs were calculated … Continue reading #Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult

Rate This

Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In … Continue reading Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

Rate This

The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Here attached you may find the takeaways of the guidelines for patients and for clinicians. takeaways for patients: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Patients.pdf takeaways for clinicians: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Clinicians.pdf Continue reading The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Rate This

Factors associated with social #isolation and being homebound among #older patients with #diabetes: a cross-sectional study

We aimed at investigating factors associated with social isolation and being homebound in older patients with diabetes.. ..Social isolation was defined as indulging in less than one interaction per week with individuals other than cohabiting family members. We defined homebound as going outside home less than once a day. To identify factors associated with social isolation and being homebound, we performed logistic regression analysis. The … Continue reading Factors associated with social #isolation and being homebound among #older patients with #diabetes: a cross-sectional study

Rate This